Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Carnaxide – page 25

674 clinical trials in Carnaxide, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Carnaxide at a glance
674
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

674 trials in Carnaxide

Open in trial search

Phase 3 study of ianalumab plus standard drug combination in adults and adolescents with systemic lupus erythematosus

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Amgen Inc.

Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Study of navenibart to prevent attacks in adults and adolescents with Hereditary Angioedema

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Navenibart
  • Sponsor:Astria Therapeutics Inc.

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Hidradenitis

Not recruiting

Long-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Dermatitis atopic

Not recruiting

Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Carnaxide

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on atherosclerotic cardiovascular disease and heart conditions, including trials evaluating new treatments for hypertrophic cardiomyopathy and pediatric heart failure.

  • Cardiovascular Disease Prevention
  • Heart Failure Management
  • Atrial Fibrillation Treatment

Research aims to reduce major cardiovascular events and improve patient outcomes through novel therapeutic approaches.

02 Nephrology Studies

Comprehensive research into kidney disorders, with a focus on IgA Nephropathy and innovative treatments for chronic kidney disease. Multiple trials are investigating new therapeutic options for patients with various forms of kidney dysfunction.

  • Kidney Transplantation
  • Lupus Nephritis
  • Glomerular Diseases

Studies aim to improve kidney function and reduce disease progression in patients with various renal conditions.

03 Metabolic Disorders

Advanced research targeting hypertriglyceridemia and related metabolic conditions. Studies focus on novel treatments for patients with severe metabolic disorders and associated cardiovascular risks.

  • Lipid Management
  • Secondary Hyperparathyroidism
  • Metabolic Disease Complications

Investigations concentrate on developing targeted therapies to address complex metabolic disorders and their complications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.